A share price of Olema Pharmaceuticals Inc [OLMA] is currently trading at $10.74, down -0.09%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The OLMA shares have gain 2.87% over the last week, with a monthly amount glided 34.25%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Olema Pharmaceuticals Inc [NASDAQ: OLMA] stock has seen the most recent analyst activity on October 08, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $20. Previously, Citigroup reaffirmed its Buy rating on August 12, 2025, and elevated its price target to $21. On April 02, 2024, Goldman initiated with a Buy rating and assigned a price target of $24 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $20 on January 30, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $21 as its price target on July 21, 2023. CapitalOne started tracking with a Overweight rating for this stock on May 05, 2023, and assigned it a price target of $16. In a note dated February 22, 2023, Credit Suisse initiated an Outperform rating and provided a target price of $12 on this stock.
Olema Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $2.86 and $13.51. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Olema Pharmaceuticals Inc [NASDAQ: OLMA] shares were valued at $10.74 at the most recent close of the market. An investor can expect a potential return of 86.22% based on the average OLMA price forecast.
Analyzing the OLMA fundamentals
Gross Profit Margin for this corporation currently stands at -0.11% with Operating Profit Margin at -431.66%, Pretax Profit Margin comes in at -390.92%, and Net Profit Margin reading is -390.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.43 and Total Capital is -0.45. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Olema Pharmaceuticals Inc [NASDAQ:OLMA] is 15.22. In addition, the Quick Ratio stands at 15.22 and the Cash Ratio stands at 1.58.
Transactions by insiders
Recent insider trading involved Harmon Cyrus, Director, that happened on Sep 18 ’25 when 10000.0 shares were sold. Director, Harmon Cyrus completed a deal on Sep 16 ’25 to sell 10000.0 shares. Meanwhile, Director Harmon Cyrus sold 3086.0 shares on Sep 18 ’25.
